Please use this identifier to cite or link to this item: https://hdl.handle.net/1/1391
Title: Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial
Authors: Roger, Simon D ;Macdougall, I.C.;Bock, A.H.;Carrera, F.;Eckardt, K.U.;Gaillard, Carlo ;Wyck, D.V.;Meier, Y.;Larroque, S.;Perrin, A.
Affliation: Central Coast Local Health District
Gosford Hospital
Issue Date: Dec-2017
Source: 88(12):301-310
Journal title: Clinical Nephrology
Department: Renal
Abstract: AIMS: To evaluate erythropoietic response rates to oral iron over time in iron-deficient anemic patients with nondialysis-dependent chronic kidney disease (ND-CKD). MATERIALS AND METHODS: FIND-CKD was a 1-year, randomized, multicenter trial of iron therapy in patients with ND-CKD, anemia, and iron deficiency, without erythropoiesis-stimulating agent (ESA) therapy. Patients with active infection or C-reactive protein > 20 mg/L were excluded. In this post-hoc analysis, response was defined as >/= 1 g/dL increase in hemoglobin (Hb) from baseline, before initiation of alternative anemia therapy (i.e., ESA, transfusion, or intravenous iron). RESULTS: 308 patients received oral iron (200 mg elemental iron/day). Mean (SD) Hb at baseline was 10.4 (0.7) g/dL. At week 4, Hb data were available from 292 patients without alternative anemia therapy: 63/292 (21.6%) showed a response. Among the 229 nonresponders at week 4, 48.8% showed a cumulative response on >/= 1 occasion by week 52 (11.1%, 19.9%, 25.9%, and 28.7% had a response at weeks 8, 12, 24, and 52, respectively), and 27.9% had received alternative iron therapy by week 52. Baseline levels of Hb, ferritin, and transferrin saturation were lower in responders than in nonresponders. Neither concomitant medication nor adherence (as assessed by medication count) was substantially different between early responders and nonresponders. CONCLUSION: Four weeks after starting oral iron therapy, only 21.6% of anemic patients with ND-CKD and iron deficiency showed an Hb increase of at least 1 g/dL. Among early nonresponders, < 30% responded at any subsequent time point. Earlier consideration of alternative therapy could improve anemia management in this population..
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1391
DOI: 10.5414/cn109198
Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/29092739
ISSN: 0301-0430
Publicaton type: Journal Article
Keywords: Kidney Disease
Drug Therapy
Study or Trial: Randomized Controlled Clinical Trial/Controlled Clinical Trial
Appears in Collections:Renal Medicine

Show full item record

Page view(s)

16
checked on Jan 28, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.